Hydralazine/magnesium valproate off-label use

Hydralazine/magnesium valproate off-label use Reactions 1680, p159 - 2 Dec 2017 Hydralazine/magnesium valproate off- label use Skin rash: case report In a study, a patient [age and sex not stated] was described, who developed a skin rash following the off-label use of hydralazine and magnesium valproate [Transkrip; routes and time to reaction onset not stated; not all dosages stated]. The patient was diagnosed with myelodysplastic syndrome (MDS). The patient was started on combination therapy with daily dose hydralazine slow release formulation tablets and magnesium valproate slow release tablets 700mg, 30mg/kg three times daily for myelodysplastic syndrome; both drugs were administered 5 days a week. However, the patient developed a skin rash. The skin rash disappeared without any corrective treatment. Author comment: "The aim of this study is to evaluate the clinical efficacy and safety of hydralazine, [magnesium valproate] in a case series of MDS patients treated in a compassionate manner." "All patients were informed that the administration of this drug combination was off-label". "Most toxicity was transient, grade 1–2, and did not require dose reduction or interruption of treatment." "[O]nly one patient developed a skin rash that disappeared without treatment." Candelaria M, et al. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIPTM) as epigenetic treatment for myelodysplastic syndrome (MDS). Annals of Hematology 96: 1825-1832, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1007/s00277-017-3103-x - Mexico 803284622 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Hydralazine/magnesium valproate off-label use

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/hydralazine-magnesium-valproate-off-label-use-8NKYQJpGPe
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39090-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p159 - 2 Dec 2017 Hydralazine/magnesium valproate off- label use Skin rash: case report In a study, a patient [age and sex not stated] was described, who developed a skin rash following the off-label use of hydralazine and magnesium valproate [Transkrip; routes and time to reaction onset not stated; not all dosages stated]. The patient was diagnosed with myelodysplastic syndrome (MDS). The patient was started on combination therapy with daily dose hydralazine slow release formulation tablets and magnesium valproate slow release tablets 700mg, 30mg/kg three times daily for myelodysplastic syndrome; both drugs were administered 5 days a week. However, the patient developed a skin rash. The skin rash disappeared without any corrective treatment. Author comment: "The aim of this study is to evaluate the clinical efficacy and safety of hydralazine, [magnesium valproate] in a case series of MDS patients treated in a compassionate manner." "All patients were informed that the administration of this drug combination was off-label". "Most toxicity was transient, grade 1–2, and did not require dose reduction or interruption of treatment." "[O]nly one patient developed a skin rash that disappeared without treatment." Candelaria M, et al. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIPTM) as epigenetic treatment for myelodysplastic syndrome (MDS). Annals of Hematology 96: 1825-1832, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1007/s00277-017-3103-x - Mexico 803284622 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off